NEWBURY PHARMACEUTICALS AB |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.22 SEK | +0.62% |
|
0.00% | +4.89% |
| 04-10 | Newbury Pharmaceuticals AB Reports Earnings Results for the Second Quarter and Six Months Ended February 29, 2024 | CI |
| 02-22 | Newbury Pharmaceuticals Secures SEK9 Million Sales Order | MT |
Valuation
| Fiscal Period: August | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| Capitalization 1 | 78.08 | 78.11 | - | - |
| Enterprise Value (EV) 1 | 78.08 | 105.1 | 117.1 | 121.1 |
| P/E ratio | - | - | - | - |
| Yield | - | - | - | - |
| Capitalization / Revenue | 7.61 x | 2.03 x | 1.08 x | 0.56 x |
| EV / Revenue | 7.61 x | 2.74 x | 1.62 x | 0.87 x |
| EV / EBITDA | -4.26 x | -14 x | 21.7 x | 6.06 x |
| EV / FCF | - | -5.53 x | -39 x | 30.3 x |
| FCF Yield | - | -18.1% | -2.56% | 3.3% |
| Price to Book | - | - | - | - |
| Nbr of stocks (in thousands) | 19,521 | 24,259 | - | - |
| Reference price 2 | 4.000 | 3.220 | 3.220 | 3.220 |
| Announcement Date | 23-10-11 | - | - | - |
1SEK in Million2
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: August | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Net sales 1 | - | 10.27 | 38.4 | 72.4 | 139.5 |
| EBITDA 1 | - | -18.33 | -7.5 | 5.4 | 20 |
| EBIT 1 | - | -19.59 | -8.6 | 4.1 | 18.5 |
| Operating Margin | - | -190.79% | -22.4% | 5.66% | 13.26% |
| Earnings before Tax (EBT) 1 | -14.67 | - | -10 | 4 | 19 |
| Net income 1 | -14.67 | -19.43 | -10.1 | 3.2 | 14.7 |
| Net margin | - | -189.28% | -26.3% | 4.42% | 10.54% |
| EPS | - | - | - | - | - |
| Free Cash Flow 1 | - | - | -19 | -3 | 4 |
| FCF margin | - | - | -49.48% | -4.14% | 2.87% |
| FCF Conversion (EBITDA) | - | - | - | - | 20% |
| FCF Conversion (Net income) | - | - | - | - | 27.21% |
| Dividend per Share | - | - | - | - | - |
| Announcement Date | 22-10-13 | 23-10-11 | - | - | - |
1SEK in Million
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: August | 2023 Q1 | 2023 Q2 |
|---|---|---|
| Net sales 1 | 0.337 | 1.501 |
| EBITDA | -5.442 | - |
| EBIT | -5.741 | - |
| Operating Margin | -1,703.56% | - |
| Earnings before Tax (EBT) | - | - |
| Net income 1 | - | -4.842 |
| Net margin | - | -322.58% |
| EPS | - | - |
| Dividend per Share | - | - |
| Announcement Date | 23-01-11 | 23-04-12 |
1SEK in Million
Estimates
Balance Sheet Analysis
| Fiscal Period: August | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Net Debt 1 | - | - | 27 | 39 | 43 |
| Net Cash position 1 | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | -3.6 x | 7.222 x | 2.15 x |
| Free Cash Flow 1 | - | - | -19 | -3 | 4 |
| ROE (net income / shareholders' equity) | - | - | -22% | 10% | 72% |
| ROA (Net income/ Total Assets) | - | - | - | - | - |
| Assets 1 | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - |
| Capex | - | - | - | - | - |
| Capex / Sales | - | - | - | - | - |
| Announcement Date | 22-10-13 | 23-10-11 | - | - | - |
1SEK in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Chiffre d''affaires - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +4.89% | 7.41M | |
| -12.59% | 8.23B | |
| +26.58% | 1.26B | |
| -13.82% | 339M | |
| +0.36% | 267M | |
| +8.33% | 220M | |
| -45.37% | 82.2M | |
| -18.35% | 78.45M | |
| +26.03% | 62.1M |
- Stock Market
- Equities
- NEWBRY Stock
- Financials Newbury Pharmaceuticals AB
